About this trial
Objective: This study aims to develop and test a novel artificial intelligence-based prediction model. This model will integrate cardiac magnetic resonance imaging and clinical data to predict the long-term risk of major adverse cardiovascular events in patients who have undergone emergency percutaneous coronary intervention for ST-segment elevation myocardial infarction.
Description: This study plans to enroll patients with STEMI who have received primary PCI. Approximately one week after the procedure, patients will undergo a cardiac magnetic resonance scan. Concurrently, we will collect patients' basic information, blood test results during treatment, and procedural records. Thereafter, patients will be followed up regularly (every six months) to record the occurrence of any major adverse cardiac events, such as cardiovascular death, recurrent myocardial infarction, hospitalization for heart failure, or unplanned repeat revascularization.All collected data, including clinical data and analyzed cardiac MR images, will be used to construct a multimodal deep learning model. The model will learn to identify features associated with future cardiac problems. The accuracy of the model will be tested and validated in different patient groups.
Potential Impact: If successful, this prediction tool could assist physicians in identifying high-risk patients earlier and more accurately, enabling closer monitoring and more timely interventions, ultimately improving the long-term prognosis for these patients.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
None
Disqualifiers
None
Trial population
Adults over 18 with a first-time, primary PCI-treated STEMI, confirmed by biomarker and ECG criteria. Patients must be clinically stable (Killip class ≤ III) at presentation, have received guideline-adherent care, and provided informed consent for CMR and follow-up.
Trial design
Cohort
Prospective
Treatments tested in this trial
Not listed
Trial groups
Trial outcomes
Primary outcomes
major adverse cardiac events
major adverse cardiac events, such as cardiovascular death, recurrent myocardial infarction, hospitalization for heart failure, or unplanned repeat revascularization.
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Qian geng
Lead sponsor
Chinese PLA General Hospital
Sponsor institution
Xi'an Jiaotong University
Collaborator
Beijing Anzhen Hospital
Collaborator
Second Affiliated Hospital of Nanchang University
Collaborator
First People's Hospital of Yulin
Collaborator
Guizhou Provincial People's Hospital
Collaborator
Jiangxi Provincial People's Hopital
Collaborator
First Affiliated Hospital of Xinjiang Medical University
Collaborator
People's Hospital of Xinjiang Uygur Autonomous Region
Collaborator
Beijing Chao Yang Hospital
Collaborator
Wuhan Asia Heart Hospital
Collaborator
This trial is not recruiting at the moment. You can still explore other options: